| Recruitment status | Enrolling by invitation |
| Unique ID issued by UMIN | UMIN000014041 |
| Receipt No. | R000016285 |
| Official scientific title of the study | The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease. |
| Date of disclosure of the study information | 2014/05/22 |
| Last modified on | 2017/11/23 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | The combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease. | |
| Title of the study (Brief title) | PSL/CYA combination therapy for VKH disease | |
| Region |
|
|
| Condition | ||
| Condition | Vogt-Koyanagi-Harada disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate the efficacy of the combination therapy of prednisolone and cyclosporine for initial onset of Vogt-Koyanagi-Harada disease. |
| Basic objectives2 | Safety,Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | Exploratory |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Proportion of subjects showing recurrences of uveitis with VKH disease |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Active |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 2 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | 1.The group given only prednisolone
mPSL 1000mg Intravenous Infusion 3 days PSL 0.6-0.7mg/kg Oral Administrarion 10 days PSL 0.5-0.6mg/kg Oral Administrarion 10 days PSL 0.4-0.5mg/kg Oral Administrarion 10 days PSL 0.3-0.4mg/kg Oral Administrarion 4 weeks PSL 0.2-0.3mg/kg Oral Administrarion 4 weeks PSL 0.1-0.2mg/kg Oral Administrarion 4 weeks PSL 0.05-0.1mg/kg Oral Administrarion 8 weeks PSL 0.05-0.1mg/kg every other day Oral Administrarion 4 weeks |
|
| Interventions/Control_2 | 2.The group given combination of prednisolone and cyclosporine
In addition to "1.",CYA 3mg/kg is administered from day 4 |
|
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1.Patients of initial onset VKH disease who present all of a) to d)
a)Within 4 weeks from disease onset b)Showing anterior chamber cells maximum 2+ c)Without sunset glow fundus 2.Complete or incomplete type of VKH disease 3.Showing cerebrospinal fluid pleocytosis or meningeal irritation signs except headache alone 4.Who can recieve the treatment within 4 weeks from the disease onset |
|||
| Key exclusion criteria | 1.Renal dysfunction
2.Immunosuppressant treatment including steroid 3.Immunocompromised condition 4.Females who are pregnant or lactating patients or who are suspicious of pregnant 5.Malignant neoplasm 6.Ontraocular surgery (except for cataract surgery) or glaucoma surgery previously,or speculate to be required in the periods of this study 7.Investigator declare a subject ineligible for any sound reasons |
|||
| Target sample size | 120 | |||
| Research contact person | |
| Name of lead principal investigator | Ryoji Yanai |
| Organization | Yamaguchi University Hospital |
| Division name | Opthalmology |
| Address | 1-1-1 Minami Kogushi,Ube-city,Yamaguchi,Japan |
| TEL | 0836-22-2278 |
| sonodak@yamaguchi-u.ac.jp | |
| Public contact | |
| Name of contact person | Kazutomi Mizuuchi |
| Organization | Hokkaido University Graduate School of Medicine |
| Division name | Department of Opthalmology |
| Address | Kita-15,Nishi-7,Kita-ku,Sapporo 060-9638,Japan |
| TEL | 011-706-5944 |
| Homepage URL | |
| mizuuchi@peach.plala.or.jp | |
| Sponsor | |
| Institute | Yamaguchi University Hospital |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Yamaguchi University Hospital |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Enrolling by invitation | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000016285 |